From Scottrade:
Recent News Headlines for ANI Pharmaceuticals Inc
ANI Pharmaceuticals Announces Launch of Diphenoxylate HCl and Atropine Sulfate Tablets
Tuesday 06/20/2017 08:30 AM ET - PR Newswire via Dow Jones News
BAUDETTE, Minn., June 20, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Diphenoxylate HCl and Atropine Sulfate Tablets, 2.5mg/0.025mg. The annual U.S. market for Diphenoxylate HCl and Atropine Sulfate Tablets is approximately $56 million, per IMS Health. Prior to ANI's launch there were two companies marketing a generic version of this drug product.
ANI Pharmaceuticals Announces Launch of Diphenoxylate HCl and Atropine Sulfate Tablets
Tuesday 06/20/2017 08:30 AM ET - Dow Jones News
Dow Jones News has only provided a headline at this time.
ANI Pharmaceuticals Files 8K - Regulation FD >ANIP
Tuesday 06/20/2017 05:00 AM ET - Dow Jones News
ANI Pharmaceuticals Inc. (ANIP) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on June 19, 2017. On June 19, 2017, ANI Pharmaceuticals, Inc. (the "Company," "we" or "us") posted to its website its June 2017 Investor Presentation. We may use this presentation in our communications or at conferences. The presentation is available on our website, www.anipharmaceuticals.com, and is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated into this Item 7.01 by reference.
ANI Pharmaceuticals Files 8K - Other Events >ANIP
Monday 06/12/2017 04:21 PM ET - Dow Jones News
ANI Pharmaceuticals Files 8K - Regulation FD >ANIP
Tuesday 06/06/2017 08:31 AM ET - Dow Jones News
